Extracts from "Clinical Evidence": Chronic fatigue syndrome
- 29 January 2000
- Vol. 320 (7230) , 292-296
- https://doi.org/10.1136/bmj.320.7230.292
Abstract
Definition Chronic fatigue syndrome is characterised by severe, disabling fatigue and other symptoms, including musculoskeletal pain, sleep disturbance, impaired concentration, and headaches. Two widely used definitions of chronic fatigue syndrome (from the US Centers for Disease Control and Prevention1 and from Oxford2—see table) were developed as operational criteria for research. There are two important differences between these definitions. The British criteria insist on the presence of mental fatigue; the American criteria include a requirement for several physical symptoms, reflecting the belief that chronic fatigue syndrome has an underlying immunological or infective pathology. #### Interventions ##### Beneficial: Exercise Cognitive behavioural therapy ##### Unknown effectiveness: Corticosteroids Antidepressants Dietary supplements Oral nicotinamide adenine dinucleotide (NADH) ##### Unknown effectiveness: Immunotherapy ##### Likely to be ineffective or harmful: Prolonged rest This review is one of 87 chapters from the second issue of Clinical Evidence www.evidence.com/ View this table: Diagnostic criteria for chronic fatigue syndrome Incidence/prevalence Community and primary care based studies have reported the prevalence of chronic fatigue syndrome to be 0.2-2.6%, depending on the criteria used.3 4 Systematic population surveys have found similar rates of the syndrome in people of different socioeconomic status, and in all ethnic groups.4 5 Female sex is the only demographic risk factor (relative risk 1.3 to 1.7 depending on diagnostic criteria used).6 Aetiology The cause of chronic fatigue syndrome is poorly understood. Prognosis Studies of prognosis in chronic fatigue syndrome have focused on people attending specialist clinics, who are likely to have had the condition for longer and to have a poorer outlook. Children with the syndrome seem to have a notably better outcome:54-94% of children show definite improvement (after up to six years' follow up); 20-50% of adults show some improvement in the medium term and only 6% return to premorbid levels of functioning.7 Despite the considerable burden of morbidity associated with chronic fatigue syndrome, there is no evidence of increased …Keywords
This publication has 38 references indexed in Scilit:
- Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndromeAnnals of Allergy, Asthma & Immunology, 1999
- The role of essential fatty acids in chronic fatigue syndrome: A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFAActa Neurologica Scandinavica, 1999
- The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic reviewQJM: An International Journal of Medicine, 1997
- Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescentsJournal of Psychiatric Research, 1997
- Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndromeJournal of Allergy and Clinical Immunology, 1996
- Alpha Interferon Treatment of Patients with Chronic Fatigue SyndromeImmunological Investigations, 1996
- Red blood cell magnesium and chronic fatigue syndromeThe Lancet, 1991
- Effect of high doses of essential fatty acids on the postviral fatigue syndromeActa Neurologica Scandinavica, 1990
- The MOS Short-form General Health SurveyMedical Care, 1988
- The Sickness Impact Profile: Development and Final Revision of a Health Status MeasureMedical Care, 1981